<SEC-DOCUMENT>0001193125-18-040112.txt : 20180212
<SEC-HEADER>0001193125-18-040112.hdr.sgml : 20180212
<ACCEPTANCE-DATETIME>20180212160716
ACCESSION NUMBER:		0001193125-18-040112
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180210
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180212
DATE AS OF CHANGE:		20180212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		18596400

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d529141d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>February&nbsp;10, 2018 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Pacific
Biosciences of California, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-34899</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">16-1590339</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1305 O&#146;Brien Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, California 94025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">521-8000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;5.02.&nbsp;&nbsp;&nbsp;&nbsp;DEPARTURE OF CERTAIN DIRECTORS OR CERTAIN OFFICERS; ELECTION OF
DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;10, 2018, the board of directors of Pacific Biosciences of California, Inc. (the &#147;Company&#148;) determined that Kathy
Ordo&ntilde;ez, the Company&#146;s Chief Commercial Officer and Executive Vice President, is an executive officer for purposes of Item 401(b) of Regulation SK and an officer for purposes of the requirements of Section&nbsp;16 of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and that Kevin Corcoran, the Company&#146;s Senior Vice President, Market Development, no longer meets the definition of named executive officer or of a Section&nbsp;16 officer under
the Exchange Act. Mr.&nbsp;Corcoran will continue in his role as Senior Vice President, Market Development, and report to Ms.&nbsp;Ordo&ntilde;ez. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;8.01.&nbsp;&nbsp;&nbsp;&nbsp;OTHER EVENTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Commencement of Proposed Public Offering of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2018, the Company issued a press release announcing the commencement of an underwritten public offering of its common
stock pursuant to a shelf registration statement filed on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-219642)</FONT> with the Securities and Exchange Commission, which was declared effective
August&nbsp;18, 2017. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure update
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has updated its disclosure regarding its Legal Proceedings and Risk Factors. The revised disclosure is filed herewith
as Exhibit&nbsp;99.2 and incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT>
including the exhibits hereto, shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, which is being made only by means of a written prospectus meeting the requirements of Section&nbsp;10 of the
Securities Act, nor shall there be any sale of the Company&#146;s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such
jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;9.01.&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS AND EXHIBITS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d529141dex991.htm">Press Release, dated February&nbsp;12, 2018. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d529141dex992.htm">Legal Proceedings and Risk Factors. </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Pacific Biosciences of California, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Susan K. Barnes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Susan K. Barnes</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Executive&nbsp;Vice&nbsp;President,&nbsp;Chief&nbsp;Financial&nbsp;Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and Principal Accounting Officer</B></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;12, 2018 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d529141dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g529141g53x69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MENLO PARK, CA, February&nbsp;12, 2018, Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced that it intends to offer and sell shares of its
common stock in an underwritten public offering. Pacific Biosciences also intends to grant the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 15% of the number of shares of its common stock sold
in the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co. is acting as the sole book-running manager for the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacific Biosciences intends to use the net proceeds from the offering for general corporate purposes, including capital expenditures and working capital.
Pacific Biosciences may also use a portion of the net proceeds from the offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although it has no present commitments or agreements
to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shelf registration statement relating to the shares of common stock was previously filed with the Securities and Exchange Commission (the
&#147;SEC&#148;) and declared effective on August&nbsp;18, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC&#146;s website. Copies of the
preliminary prospectus supplement (when available) and accompanying prospectus may be obtained from Cantor Fitzgerald&nbsp;&amp; Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by <FONT
STYLE="white-space:nowrap">e-mail</FONT> at prospectus@cantor.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an
offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any
such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Pacific Biosciences of California, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacific
Biosciences offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) Technology, Pacific Biosciences&#146;
products enable <I>de novo</I> genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively
spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences&#146; technology
provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> sequencing systems, including consumables and software, provide
a simple, fast, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> workflow for SMRT Sequencing. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Safe Harbor&#148; Statement Under the Private Securities Litigation Reform Act of 1995 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties that
could cause actual results to differ materially, including, but not limited to, whether or not Pacific Biosciences will be able to raise capital through the sale of shares of common stock or consummate the offering, the final terms of the offering,
the satisfaction of customary closing conditions, prevailing market conditions, the anticipated use of the proceeds of the offering which could change as a result of market conditions or for other reasons, and the impact of general economic,
industry or political conditions in the United States or internationally. Additional risks and uncertainties relating to the proposed offering, Pacific Biosciences and its business can be found under the heading &#147;Risk Factors&#148; in Pacific
Biosciences&#146; most recent periodic, quarterly and annual reports filed with the SEC and in the preliminary prospectus supplement and accompanying prospectus relating to the offering to be filed with the SEC. Pacific Biosciences assumes no duty
or obligation to update or revise any forward-looking statements for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Contact: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pacific
Biosciences of California, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1305 O&#146;Brien Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Menlo Park, California 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(650)
<FONT STYLE="white-space:nowrap">521-8450</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d529141dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LEGAL PROCEEDINGS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;2,
2016, we filed a complaint against Oxford Nanopore Technologies Ltd., Oxford Nanopore Technologies, Inc. (&#147;ONT Inc.&#148;) and Metrichor, Ltd. (&#147;Metrichor&#148; and, together with ONT Inc., &#147;ONT&#148;) with the U.S. International
Trade Commission (&#147;USITC&#148;) for patent infringement. On December&nbsp;5, 2016, the USITC provided notice that an investigation had been instituted based on the complaint. We sought exclusionary relief with respect to several ONT products,
including ONT&#146;s MinION and PromethION devices. The complaint was based on our U.S. Patent No.&nbsp;9,404,146, entitled &#147;Compositions and methods for nucleic acid sequencing&#148; which covers novel methods for sequencing single nucleic
acid molecules using linked double-stranded nucleic acid templates, providing improved sequencing accuracy. On March&nbsp;1, 2017, we filed an amended complaint to add a second patent in the same patent family, U.S. Patent No.&nbsp;9,542,527, which
was granted on January&nbsp;10, 2017, to the investigation. We sought, among other things, an exclusion order permanently barring entry of infringing ONT products into the United States, and a cease and desist order preventing ONT from advertising
and selling infringing products in the United States. On May&nbsp;23, 2017, the Administrative Law Judge (&#147;ALJ&#148;) assigned to the matter issued an order construing certain claim terms of the asserted patents. On June&nbsp;8, 2017, ONT filed
a summary determination motion to terminate the proceedings based on the ALJ&#146;s claim construction decision, and we did not oppose the motion. The ALJ granted the motion on July&nbsp;19, 2017, and, on July&nbsp;31, 2017, we filed a petition to
review with the USITC to correct what we believe was an incorrect construction of the claims. On September&nbsp;5, 2017, the USITC issued a notice granting our petition to review the ALJ&#146;s claim construction decision. On February&nbsp;7, 2018,
the USITC issued a notice indicating that it had determined to adopt the ALJ&#146;s claim construction and terminating the investigation. We plan to appeal the USITC&#146;s ruling to the U.S. Court of Appeals for the Federal Circuit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;2, 2017, we filed a claim in the High Court of England and Wales against Oxford Nanopore Technologies Ltd. (&#147;ONT
Ltd.&#148;) and Metrichor for infringement of Patent EP(UK) 3 045 542, which is in the same patent family as the patents asserted in the USITC action referred to above. We are seeking remedies including injunctive relief, damages, and costs. On
March&nbsp;27, 2017, the defendants in the case filed their defense and counterclaim, denying infringement and seeking a declaration that the asserted patent is invalid. We filed our reply and defense to counterclaim on April&nbsp;12, 2017. A case
management conference was held on June&nbsp;13, 2017. A trial is scheduled for May 2018 (not earlier than May 8). On August&nbsp;31, 2017 we added a claim for infringement of a newly granted divisional, EP(UK) 3 170 904. On December&nbsp;22, 2017,
ONT Ltd. added to the action a request for declaration of <FONT STYLE="white-space:nowrap">non-infringement</FONT> of its 1D<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> product. On January&nbsp;12, 2018 we served reply to ONT&#146;s
request for a declaration of <FONT STYLE="white-space:nowrap">non-infringement,</FONT> asserting infringement of both patents by ONT&#146;s 1D<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;15, 2017, we filed a complaint in the U.S. District Court for the District of Delaware against ONT Inc. for patent infringement.
The complaint is based on our U.S. Patent No.&nbsp;9,546,400, entitled &#147;Nanopore sequencing using n-mers&#148; which covers novel methods for nanopore sequencing of nucleic acid molecules using the signals from multiple monomeric units. This
patent was granted on January&nbsp;17, 2017. We are seeking remedies including injunctive relief, damages and costs. On May&nbsp;8, 2017, the defendants filed a motion to dismiss the complaint, alleging that the asserted patent claims recite patent
ineligible subject matter. On November&nbsp;9, 2017, the judge denied ONT&#146;s motion to dismiss. The parties and court are currently working to define the case schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;21, 2017, ONT Ltd. and Harvard University filed a claim against us in the High Court of England and Wales for infringement of
Patent EP(UK) 1 192 453, a patent owned by Harvard University and entitled &#147;Molecular and atomic scale evaluation of biopolymers,&#148; and for which ONT Ltd. alleges it holds an exclusive license. ONT Ltd. and Harvard University are seeking
remedies including injunctive relief, damages, and costs. On April&nbsp;25, 2017, ONT Ltd. announced that it also had filed a claim against us in the District Court of Mannheim, Germany, for infringement of the German version of the patent. On
November&nbsp;2, 2017, we filed our statement of defense in the German infringement matter and we also filed a separate nullity action in Germany to establish that the EP&nbsp;1&nbsp;192&nbsp;453 patent is invalid. On December&nbsp;6, 2017, we filed
a cross-complaint in the German infringement matter alleging ONT Ltd.&#146;s infringement in Germany of our EP 3 045 542 patent. The trial date for the German infringement matter and cross-complaint is set for July&nbsp;27, 2018. The trial date for
the UK matter is expected to occur in approximately March 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, we filed a complaint in the U.S. District
Court for the District of Delaware against ONT Inc. for patent infringement. The complaint is based on our U.S. Patent No.&nbsp;9,678,056 entitled &#147;Control of Enzyme Translation in Nanopore Sequencing&#148;, granted June&nbsp;13, 2017, and U.S.
Patent No.&nbsp;9,738,929 entitled &#147;Nucleic Acid Sequence Analysis&#148;, granted August&nbsp;22, 2017. We are seeking remedies including injunctive relief, damages and costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2017, the defendants filed a motion to dismiss the complaint, alleging that the asserted patent claims in the 9,738,929
patent recite patent ineligible subject matter. On January&nbsp;5, 2018, we filed our opposition to this motion. The parties and court are currently working to define the case schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation is inherently unpredictable, and it is too early in the proceedings to predict the outcome of these lawsuits or any impact they may
have on us. As such, the estimated financial effect associated with these complaints cannot be made as of this <FONT STYLE="white-space:nowrap">8-K</FONT> filing time. Litigation is a significant ongoing expense, recognized in sales, general and
administrative expense, with an uncertain outcome, and has been in the past and may in the future be a material expense for the Company. Management believes this investment is important to protect the Company&#146;s intellectual property position,
even recognizing the uncertainty of the outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may also be involved in a variety of other claims, lawsuits,
investigations and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment and other matters that arise in the normal course of our business. In addition, third parties may, from time to time,
assert claims against us in the form of letters and other communications. We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do
not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently
unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources and other factors. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISK FACTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are involved in legal proceedings to enforce our intellectual property rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our intellectual property rights involve complex factual, scientific and legal questions. We operate in an industry characterized by
significant intellectual property litigation. Even though we may believe that we have a valid patent on a particular technology, other companies have from time to time taken, and may in the future take, actions that we believe violate our patent
rights. For example, we are involved in several legal proceedings for patent infringement with ONT, Oxford Nanopore Technologies Ltd. and Harvard University in several United States and European jurisdictions. We have received adverse rulings
against us with respect to our complaint with the USITC in one of these proceedings, and there are no assurances that we can be successful in appealing or otherwise overturning any such rulings. Legal actions to enforce our patent rights have been,
and will continue to be, expensive, and may divert significant management time and resources. Adverse parties from previous legal actions have brought, and may in the future bring, claims against us and/or our intellectual property. Litigation is a
significant ongoing expense, recognized in sales, general and administrative expense, with an uncertain outcome, and has been, and may in the future be, a material expense for the Company. Our enforcement actions may not be successful, have given
rise to legal claims against us and could result in some of our intellectual property rights being determined to be invalid or not enforceable. Furthermore, an adverse determination or judgement could lead to an award of damages against us, or the
issuance of an injunction against us that could prevent us from selling any products found to be infringing the intellectual property rights of another party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have been, are currently, and could in the future be, subject to legal proceedings with third parties who may claim that our products infringe or
misappropriate their intellectual property rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our products are based on complex, rapidly developing technologies. We may not
be aware of issued or previously filed patent applications that belong to third parties that mature into issued patents that cover some aspect of our products or their use. In addition, because patent litigation is complex and the outcome inherently
uncertain, our belief that our products do not infringe third-party patents of which we are aware or that such third-party patents are invalid and unenforceable may be determined to be incorrect. As a result, third parties have claimed, and may in
the future claim, that we infringe their patent rights and have filed, and may in the future file, lawsuits or engage in other proceedings against us to enforce their patent rights. For example, ONT and Harvard University have filed claims against
us in the High Court of England and Wales and the District Court of Mannheim, Germany for patent infringement. We are aware of other issued patents and patent applications owned by third parties that could be construed to read on our products and
services. Although we do not believe that our products or services infringe any valid issued patents, the third-party owners of these patents and applications may in the future claim that we infringe their patent rights and file lawsuits against us.
In addition, as we enter new markets, our competitors and other third parties may claim that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets. Furthermore,
parties making claims against us may be able to obtain injunctive or other relief, which effectively could block our ability to develop further, commercialize, or sell products or services, and could result in the award of substantial damages
against us. Patent litigation between competitors in our industry is common. Additionally, we have certain obligations to many of our customers and suppliers to indemnify and defend them against claims by third parties that our products or their use
infringe any intellectual property of these third parties. In defending ourselves against any of these claims, we have in the past incurred, and could in the future incur, substantial costs, and the attention of our management and technical
personnel could be diverted. For example, we previously incurred significant legal expenses to litigate and settle a complaint alleging patent infringement. Even if we have an agreement that indemnifies us against such costs, the indemnifying party
may be unable to uphold its contractual obligations. To avoid or settle legal claims, it may be necessary or desirable in the future to obtain licenses relating to one or more products or relating to current or future technologies, which could
negatively affect our gross margins. We may not be able to obtain these licenses on commercially reasonable terms, or at all. We may be unable to modify our products so that they do not infringe the intellectual property rights of third parties. In
some situations, the results of litigation or settlement of claims may require us to cease allegedly infringing activities which could prevent us from selling some or all of our products. The occurrence of these events may have a material adverse
effect on our business, financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the course of our business, we may from time to
time have access or be alleged to have access to confidential or proprietary information of others, which, though not patented, may be protected as trade secrets. Others could bring claims against us asserting that we improperly used their
confidential or proprietary information, or that we misappropriated their technologies and incorporated those technologies into our products. A determination that we illegally used the confidential or proprietary information or misappropriated
technologies of others in our products could result in us paying substantial damage awards or being prevented from selling some or all of our products, which could materially and adversely affect our business. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g529141g53x69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g529141g53x69.jpg
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M"Z\TEO<T)+,MY>K+H&U@*C-%;9/)Q&5/)*W9JB]T-?NZ::Z?M\M\X2V%:O\
M\LL:_N<Q<CL]WXLR0FW.Y.[CSZ1P[_U6[!A2&ZN<=2]G&$NBF)IE7<K"75)!
M]T73VI!;B9@+/9$E7NP7\7O!9^UAV' ZO.G*QX)XEH_:"-[W%V4UMUEU5:U3
MRHIM75+.T*0FF@&#5F59*M=3$G'Y&*H'I"TPR>M'*BO[O5NN@-!1G+9[-HB6
M"LZWLW:*2=$? ;!/7F0;CCPMU6VQ)QOM#DYOVCIV@*PCAC9@YAMW9YAW$=.E
MQ6\4MKQ92C-U:NR[J7#+4][MTJE))WM6G$)3[IG0I^;GU(WR*7!>%_EH(ZW3
M4<A^X+_%.5$=L[([KCP3]HMNEMG&,[)[*([93VSC&<ZYQG\8]8SFDHT.3SGZ
MQV0P?,(F_:CV@S;84E$ULGP;,(2K124/3;3B0H<% * /6*=\0%QRBK.]*-C8
MSW%85?$H8T):T)=Z?<CTU@=H*_QAXQD(I3&[9^T#/2#.1(X63VPFH+V34SLR
M<O4'&G*K*7D ;EG(H<"E6FO=OCZ;VE\,4_$.Q_%D\_:7JN$*>[C##M5;/9SM
M*J] 3[^T])3";.,N333+LBK(H$IF I-G4-+0Q#PY,D>=_-G<]"1%VNI$D"G5
M5&I>Y?=?5W'JUE9$T#<+[[9V^=;7:N!^VKG;\J9^57\;_A93&V1*?9S:VTGX
M;N(YZ))(_P#G?^\<*^TXZK&OLJ86QA4FTIJ2Y?9YBU7P!!;G:[3696;0D#[B
M2*X\"@?#\*=+I3;N&];Q'D[%,%*:'E+]B-][FWJ12(UC+ZR0CVK5#9@\92Z0
MQN0."BSS.^'";IFK&T6Z*&B>4E$W*N^^V-M-,9F^ENMXBVM^EHG0%.M[]JP_
M4Q&2E(N EKD(WE3L,BDH2*1A@:8%#4917553PQ0DS1EL$(O=,*JIC'KU-)+;
M=7&VH&QO B\7 U:MF+9NR9H(M6;1!%JU:MT]$6[9LW3U200013QJFDBBEIJF
MDGIKKIIIKKKKC&,8QZB)@0I;Q;6TWEUT'SI,[H&NE>NY.^"!EL!2$(MBLVBX
MV/6_7LG9;ZD(U-/UN1Z#MP@ANF]6&)*/\O&SI\R<6S&PZ7\0>!]?2(MOZ_I&
M-=<[=+DQ:D0*=M3#:%N$=ASQ\'J&O0=N. N^OPJ-=++:JJ"V)91K^4=I(-@#
M0OHMG+U!5%[^%L+C^G7O/TA8\^7#UO\ 77<U.3J['#>;8]"]G$,BW-$VVFD6
M!L4M7^#;E6,R>/.T#3]ZMEXJZ).)2_/%"^^[A^0+[+.'.VZCI93U%]]^/[@_
MI"V[IZ_7SC?*+ID=1D2.1,8;>GD#EB6)8:KQ\U0:+(.[#EI.6.QNB;?=33=N
M-7)[LVZVV<*K(I:J*ZZ[[9QB#K\OD+1/\_/6)<M,CKCS5&2!MZ%_U5<\'N9C
M])J@Y_;D81J6U;!'?S[Z?79/OVV^5W2/O72^'3X]-O=G\2#:_4$><(T"Q.:'
M!BQ7MS4[9\BHNUS@P<%F1<(&"2R&V,+#)[HA-; @,@3U'F2P%OONR"2461 R
M-B.4W&[%%V&K=NW7X$7'TB".MO7KNC#1[E^2&K B-D]"W08O$O7!#8U6\4;P
MX'7%91*3;-U6NDRS#Q#PT]D4P8-EW"(0Q(Y&21 ?9<KB![1[NFZ17Y"U_7KG
M"VMSK;=Z]=;P7_J(F)Z0B>D(GI")Z0B>D(GI")Z0B>D(^8P^J I0/DA8TN7:
MJ-'-;=@QV*M]5-,Z8=!QULC=0!1#&WXSEF8!;#BS%3.,?*R>MU?QCW_CU\[E
M*)C*=Z70/_?0^(UCWL9Q++XQV&NXHEG$N-US9G.U!920>SF7L./F<EUD7 =E
M9L/RSPN<KK2TWTAEWE;YF\DTQ[9Z&2@]2];3FE)[-M"$+;0,19<UK(D&=@Q"
M.V=6L5R6C M+9VFZPY9DTV"J2F%=W*&F,YVSDS+<P7G,J75(41;*%%)%ARN/
MVXQP1[.^/-A=+V58*55\1[.*3BJCTHL51RL3-"I5>8FFYR96 7*A[M/S"@VI
MLMN,*>2H%(;6;6'\W.E'O?#_  V4=H=7K@XMU:9KV5Q'CGF;!849L)E*)N(=
MQM]<MA#A;IZC&XS&PST@UU8NW/S.D7I<0_\ ULD6##EC:/=4J>=L'"DAINXS
M7.F=5MP'[[C81?&^+&O:7JE/V6[.D3=0V=RM:IU2VG8\]VF)6BNT^DS+<\UA
MBBOS#;2IZ?GIIIESMFV\K:VI:99[>13-/I"&KJL\A?8')$3J"GJ2D=K\^5?=
M<O.C#47!#E2;6TI #&NY(S,''11%ZY0T$2 8[SA=KHR;Y?I[;/-E<*:::*43
M#K02E!4VE9(( ^\1KJ3KOCEC$&(=BVS3:14L2XFQ7(X=QG7\*TR4F)2H3;Z9
M=S#\E-OMR+LM*-RZVFUF9DWV_@<+JPR0&@D@DW>?N; GB)WSV1V\3AJ/2D=C
MQA3E;CH3)@TKG!"?G!+P0+L:ULQQ\1&1B&1ML^<.V^VC]RI]K.7*+QO*18F/
ME-5#8E?M7BGM /LV@H%68[E*M< #QUZBQXGQGCJ;]I,#9ALGEZHO L].RR=H
M6TV9D)JG4EBCRDRW,OT3#PGF6'Y^J3RV4-KS,H3V=D%IR0F)F=E]I_QV8++K
MG\A5E]!R51T5V@-<SN72F2K:?G[EA6Z;1#-$G.VFNJ:;LXQ>3PMK_6NNV!#G
M737\?_-I!)6^IPZY4DD_W+/^8P?;8J]-POL7H.#)%+<N*Q6Z13:?(I-NSHN&
MY14TXIL$W+<H\U2)8[[>\MW//N:];Q'DK".?(5T'VXS\@7$O%G(UWP&B4.C*
MPOJ92>7SFH ]MH-G]4"DY$QU1%D" ATGH\8M'@[.K8FWTT6=)NU=%O@^+=%P
MD92HW-B!8$#?X&*6Z,OKRP>-+6FKPZ%O_G'L3GJ5WI6]-6G#(W0SRE+2 ,++
M**B&$FKY\&E1H4;)#'*7NV&%=%<.M]T&N!^6[AT8#H )5>V8$ D7((T''06@
MM1_;T_ >5?J_G6QI9'@O+U"<)Q;I53=P"9(/XZ6UD3'68R,I)$4MBKL0SCF"
M+C8=OE1!#"654D\J:X_**VT!XDD>03;ZP-%#6!Y7?*#$U>H:;Z7@WC=Y9EQ0
MS_QSB&.<(1T;=UFP043=B6-BVHM99EG&HBA)G+-=\&$133"FPOX\:[N661TK
MD+Y>O7.+D)3H05'CK8#H-->IW<N<7GREV3U)5W7I7QT^0[>OY5:IFLRER\S=
M,U5'G<1B71=?QM5=.9 9# MUWR,1MN()-7Q<F& *?IW 5@^41:I-T 9N8H@@
M9<R;VO8@ZV/#6VH^?G O\I6;Y2?*U4[WLBDNY:RX9I&6S:P =(4E'.6Z[Z%D
M[F+P65E8FV)75,[(/MW@J3EWP9RJ]%0]JR:8&KLRS'5HD[;M=D2<J38IN0!<
MYM-1?2PX7T/R@H:&\A-XT]RGV58/DHK3>$6%P9)I#'Y7/H+$Y#'*TZ9C"+)!
M6N)S3.94BT9NB%AE'#:*J#F3[<0/D3X4L[S'-2RH &B"FY 2;YMUR+CH8JVJ
M(/YL^OJZ =($^V:EX):V2&9S:MN6XERC![Z_CL-.-M"L086[9-G&&$FTEQ .
MNR4D[6+,F20QPZ4V2:"WJ:\<'HDY!I8JM^*]@>X6/AK%46YY*.\ZB\<GD,D%
MQUN"J;MWA&1UK%DK,"0<T^Y^NZ.3^Q(@'C5KU@A-&F615N;C#TXC(H^DZ?\
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M3G-Q4;=W87#\QM4HJ>MA'BV^G-/12RI$YW4W=R23PLA')?&$S[K9559<D &
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<$TFK$>P9H(M&;-LDDW;-DDT44]$]-=<(I'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
